Background: Vascular diseases, including atherosclerosis, are the leading cause of death in the US and world-wide. A quiescent population of fibroblasts that reside in the adventitia (AdvFib) activates and expands upon different vascular insults and contribute to the progression of vascular diseases. However, what regulates AdvFib’s activation remains unknown. We designed a genome-wide CRISPRi screen on human AdvFib to identify these regulators. Methods: We generated an immortalized human coronary AdvFib line that stably expresses dCas9-KRAB, which effectively silences any genes of interest. These cells were infected with a pool of lentivirus carrying guide RNAs (gRNA) covering the entire transcriptome at 200X coverage and allowed to expand freely. Frequency of gRNAs was assessed at different cell passages to identify those that influence AdvFib activation and was followed by experimental validation. Lastly, bioinformatic analysis was performed to determine regulatory pathways and gene networks involved in AdvFib activation. Results: Comparing relative gRNA abundances from early to late passages revealed several hundred putative regulators of AdvFib activation. GO biological process analysis of the top 250 enriched gRNA targets demonstrated disproportionate representation of cyclin inhibitors, validating the effectiveness of our screening. Molecular signatures for adipogenesis and key regulators of tissue mineralization including IBSP and ENPP1 were notably enriched in our screen. Human disease association using PhenGenI revealed a significant association with atherosclerosis. Indeed, numerous coronary artery disease GWAS genes including TCF21 , ZEB2 , CDKN1A , and CDKN2A were enriched in our screen, providing additional support for AdvFib’s importance in atherosclerosis. These hits were subsequently validated individually in vitro. Conclusion: A genome-wide CRISPRi screen of AdvFib activation modulators identified numerous potential regulator genes, many of which have known genetic and observational association with human vascular diseases. This study affirms the potentially important role of AdvFib in human vascular disease and may pave the way to future therapeutics targeting this often neglected cell population.